Zydus Lifesciences (ZYDUSLIFE.NS) Stock Price

Zydus Lifesciences Price

🇮🇳NSE·CLOSED
1,112.00INR
Market closed
Today +/-
Today %

Zydus Lifesciences (ZYDUSLIFE.NS) Stock | ISIN INE010B01027. The current Zydus Lifesciences stock price is 1,112 INR (2026). Revenue is 264.71 B INR. Net income is 46.17 B INR. The P/E ratio is 24.24. Market capitalization is 1.12 T INR. Zydus Lifesciences operates in the Health sector.

Zydus Lifesciences stock price

Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Zydus Lifesciences over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Zydus Lifesciences stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Zydus Lifesciences's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Zydus Lifesciences Stock Price History
DateZydus Lifesciences Price
Access this data via the Eulerpool API
Get Free API Key

Zydus Lifesciences Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2006
14.45 B INR
1.71 B INR
1.52 B INR
Jan 1, 2007
17.86 B INR
2.27 B INR
2.34 B INR
Jan 1, 2008
22.66 B INR
3.05 B INR
2.58 B INR
Jan 1, 2009
28.62 B INR
4.54 B INR
3.03 B INR
Jan 1, 2010
35.74 B INR
6.08 B INR
5.05 B INR
Jan 1, 2011
46.31 B INR
9.01 B INR
7.11 B INR
Jan 1, 2012
52.63 B INR
9.43 B INR
6.53 B INR
Jan 1, 2013
63.58 B INR
9.45 B INR
6.54 B INR
Jan 1, 2014
72.24 B INR
10.02 B INR
8.04 B INR
Jan 1, 2015
86.51 B INR
14.83 B INR
11.51 B INR
Jan 1, 2016
96.17 B INR
20.39 B INR
19.34 B INR
Jan 1, 2017
95.72 B INR
15.32 B INR
14.88 B INR
Jan 1, 2018
119.54 B INR
23.11 B INR
17.76 B INR
Jan 1, 2019
131.66 B INR
23.82 B INR
18.49 B INR
Jan 1, 2020
142.53 B INR
21.02 B INR
11.77 B INR

Zydus Lifesciences Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 10, 2026, 6:27 PM
 
REVENUE (M INR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M INR)
NET INCOME (M INR)
NET INCOME GROWTH (%)
DIV. (INR)
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Zydus Lifesciences generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Zydus Lifesciences retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Zydus Lifesciences's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Zydus Lifesciences has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Zydus Lifesciences's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Zydus Lifesciences stock margins

The Zydus Lifesciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Zydus Lifesciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Zydus Lifesciences.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2006
55.13 %
11.8 %
10.54 %
Jan 1, 2007
56.79 %
12.69 %
13.09 %
Jan 1, 2008
58.17 %
13.45 %
11.37 %
Jan 1, 2009
60.39 %
15.86 %
10.59 %
Jan 1, 2010
59.61 %
17.01 %
14.13 %
Jan 1, 2011
63.58 %
19.46 %
15.35 %
Jan 1, 2012
63.24 %
17.92 %
12.4 %
Jan 1, 2013
58.69 %
14.87 %
10.28 %
Jan 1, 2014
58.23 %
13.87 %
11.12 %
Jan 1, 2015
58.64 %
17.14 %
13.3 %
Jan 1, 2016
60.71 %
21.21 %
20.11 %
Jan 1, 2017
57 %
16 %
15.54 %
Jan 1, 2018
59.95 %
19.33 %
14.85 %
Jan 1, 2019
59.71 %
18.09 %
14.04 %
Jan 1, 2020
61.36 %
14.74 %
8.26 %

Zydus Lifesciences Stock Revenue, EBIT, Earnings per Share

The Zydus Lifesciences earnings per share therefore indicates how much revenue Zydus Lifesciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2006
15.34 INR
1.81 INR
1.62 INR
Jan 1, 2007
18.95 INR
2.4 INR
2.48 INR
Jan 1, 2008
24.06 INR
3.23 INR
2.73 INR
Jan 1, 2009
27.95 INR
4.43 INR
2.96 INR
Jan 1, 2010
34.9 INR
5.94 INR
4.93 INR
Jan 1, 2011
45.22 INR
8.8 INR
6.94 INR
Jan 1, 2012
51.4 INR
9.21 INR
6.37 INR
Jan 1, 2013
62.09 INR
9.23 INR
6.38 INR
Jan 1, 2014
70.55 INR
9.79 INR
7.85 INR
Jan 1, 2015
84.49 INR
14.48 INR
11.24 INR
Jan 1, 2016
93.92 INR
19.92 INR
18.89 INR
Jan 1, 2017
93.48 INR
14.96 INR
14.53 INR
Jan 1, 2018
116.74 INR
22.57 INR
17.34 INR
Jan 1, 2019
128.57 INR
23.26 INR
18.05 INR
Jan 1, 2020
139.19 INR
20.52 INR
11.49 INR

Zydus Lifesciences business model & stock analysis

Zydus Lifesciences Ltd is an Indian pharmaceutical company based in Ahmedabad, Gujarat. It was founded in 1995 and has since become one of the leading pharmaceutical companies in India. The company operates both domestic and international markets and offers a wide range of pharmaceutical products and services. History: Zydus Lifesciences Ltd was founded in 1995 by Pankaj Patel with the aim of producing affordable and high-quality medications. Over the years, the company has expanded its portfolio and is now one of the leading companies in the Indian pharmaceutical industry. The company has also carried out several acquisitions and mergers to expand its business. Business model: Zydus Lifesciences Ltd is an integrated pharmaceutical company that manufactures both generic and proprietary products. It operates throughout the value chain from research and development to production and marketing of drugs. The company has a strong presence in the domestic market and is also expanding into the US, Europe, and other parts of the world. Divisions: Zydus Lifesciences Ltd is divided into various divisions to manage its wide range of products and services. Here are some of the main divisions of the company: 1. Drug production: Zydus Lifesciences Ltd produces a wide range of generic and proprietary drugs for various indications such as diabetes, cardiovascular diseases, neurological disorders, oncology, gastroenterology, and infectious diseases. 2. Research and development: The company has a dedicated team of researchers and scientists who constantly develop new and innovative products. It also has state-of-the-art research and development facilities. 3. Biologics: The company also produces biopharmaceuticals such as monoclonal antibodies and recombinant proteins for various indications. 4. Diagnostics: Zydus Lifesciences Ltd also produces diagnostic products such as pregnancy tests and tests for infectious diseases. 5. Animal health: The company is also involved in the animal health industry and produces medications for animals. Products: The company offers a wide range of pharmaceutical products and services. Here are some of the main products of Zydus Lifesciences Ltd: 1. Metformin: Zydus Lifesciences Ltd produces metformin for the treatment of diabetes. 2. Clopidogrel: The company also produces clopidogrel for the treatment of cardiovascular diseases. 3. Doxycycline: Zydus Lifesciences Ltd also produces doxycycline for the treatment of infectious diseases. 4. Zidovudine: The company also produces zidovudine for the treatment of HIV/AIDS. 5. Biopharmaceuticals: Zydus Lifesciences Ltd produces various biopharmaceuticals such as monoclonal antibodies and recombinant proteins for various indications. Summary: Zydus Lifesciences Ltd is a leading Indian pharmaceutical company with a wide portfolio of drugs and services. The company has a strong presence in the domestic market and is expanding into the US, Europe, and other parts of the world. It is divided into various divisions to manage its wide range of products and services. It is also involved in the animal health industry and produces medications for animals. Answer: Zydus Lifesciences Ltd is a leading Indian pharmaceutical company that offers a wide range of drugs and services in domestic and international markets.

Zydus Lifesciences SWOT Analysis

Strengths

  • Strong product portfolio with a diverse range of pharmaceutical and healthcare products.
  • Established presence in both domestic and international markets.
  • Robust research and development capabilities, allowing for continuous innovation.
  • Strong financial performance and stability.
  • Well-established distribution network, ensuring wide market reach.

Weaknesses

  • Relatively limited brand recognition compared to some competitors.
  • Dependence on a few key suppliers for raw materials.
  • Vulnerability to changes in government regulations and policies.
  • Limited geographical presence in certain regions, potentially missing out on market opportunities.

Opportunities

  • Growing demand for generic pharmaceuticals in emerging markets presents significant growth opportunities.
  • Increasing focus on research and development for novel drugs and therapies.
  • Strategic partnerships and collaborations with other pharmaceutical companies to expand market presence.
  • Technological advancements in the healthcare industry open avenues for new product development.

Threats

  • Intense competition from both domestic and international pharmaceutical companies.
  • Regulatory challenges and increasing scrutiny on drug pricing and affordability.
  • Counterfeit drugs and intellectual property rights violations pose risks to the company's reputation.
  • Economic uncertainties and fluctuations in currency exchange rates impacting the company's profitability.

Zydus Lifesciences Eulerpool Fair Value

Zydus Lifesciences historical P/E ratio, EBIT multiple, and P/S ratio

Zydus Lifesciences annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Zydus Lifesciences shares outstanding

The number of shares was Zydus Lifesciences in 2025 — This indicates how many shares 1.006 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2006
942 M base_Shares
Jan 1, 2007
942 M base_Shares
Jan 1, 2008
942 M base_Shares
Jan 1, 2009
1.02 B base_Shares
Jan 1, 2010
1.02 B base_Shares
Jan 1, 2011
1.02 B base_Shares
Jan 1, 2012
1.02 B base_Shares
Jan 1, 2013
1.02 B base_Shares
Jan 1, 2014
1.02 B base_Shares
Jan 1, 2015
1.02 B base_Shares
Jan 1, 2016
1.02 B base_Shares
Jan 1, 2017
1.02 B base_Shares
Jan 1, 2018
1.02 B base_Shares
Jan 1, 2019
1.02 B base_Shares
Jan 1, 2020
1.02 B base_Shares

Zydus Lifesciences Dividend History

26 years of dividend payments

YearAnnual DividendYoY ChangePayments
202511INR↑ 266.7%1×
Jul 25, 202511INR↑ 266.7%1/1
20243INR↓ 50.0%1×
20236INR↑ 140.0%1×
20222.5INR↓ 28.6%1×
20213.5INR 0.0%1×
20203.5INR 0.0%1×
20193.5INR 0.0%1×
20183.5INR↑ 9.4%1×
20173.2INR 0.0%1×
20163.2INR↓ 73.3%1×

Zydus Lifesciences dividend history and estimates

In 2025, Zydus Lifesciences paid a dividend amounting to 11 INR. Dividend means that Zydus Lifesciences distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2006
6 INR
0 INR
Jan 1, 2007
4 INR
0 INR
Jan 1, 2008
4.5 INR
0 INR
Jan 1, 2009
4.5 INR
0 INR
Jan 1, 2010
5 INR
0 INR
Jan 1, 2011
6.25 INR
0 INR
Jan 1, 2012
7.5 INR
0 INR
Jan 1, 2013
7.5 INR
0 INR
Invalid Date
9 INR
-6 INR
Jan 1, 2015
12 INR
0 INR
Jan 1, 2016
3.2 INR
0 INR
Invalid Date
3.2 INR
3.2 INR
Invalid Date
0 INR
3.5 INR
Jan 1, 2019
3.5 INR
0 INR
Jan 1, 2020
3.5 INR
0 INR

Zydus Lifesciences dividend payout ratio

In 2025, Zydus Lifesciences had a payout ratio of 12.25%. The payout ratio indicates the percentage of the company's profits that Zydus Lifesciences distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2006
24.69 %
Jan 1, 2007
21.5 %
Jan 1, 2008
21.98 %
Jan 1, 2009
20.27 %
Jan 1, 2010
20.28 %
Jan 1, 2011
17.99 %
Jan 1, 2012
23.55 %
Jan 1, 2013
23.51 %
Jan 1, 2014
22.93 %
Jan 1, 2015
21.39 %
Jan 1, 2016
16.94 %
Jan 1, 2017
22.04 %
Jan 1, 2018
20.18 %
Jan 1, 2019
19.38 %
Jan 1, 2020
30.46 %
Price targets and forecasts for Zydus Lifesciences are not yet available.

Zydus Lifesciences Earnings Estimates

Zydus Lifesciences Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
5/16/20248.28INR52.72 BINR2024 Q4
2/1/20247.58INR47.34 BINR2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Zydus Lifesciences stock

74/100
83
Environment
83
Social
55
Governance
E

Environment

20
Scope 1 - Direct Emissions67,705.11
Scope 2 - Indirect emissions from purchased energy239,708.53
Scope 3 - Indirect emissions within the value chain24,393
Total CO₂ emissions307,413.64
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees7.56
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Zydus Lifesciences shareholder structure

% Name
74.96431%
Zydus Family Trust
Zydus Family Trust
4.62314%
Life Insurance Corporation of India
Life Insurance Corporation of India
1.7351%
ICICI Prudential Asset Management Co. Ltd.
ICICI Prudential Asset Management Co. Ltd.
1.49215%
PPFAS Asset Management Private Limited
PPFAS Asset Management Private Limited
1.22532%
Kotak Mahindra Asset Management Company Limited
Kotak Mahindra Asset Management Company Limited
0.82169%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.57631%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
0.47574%
Norges Bank Investment Management (NBIM)
Norges Bank Investment Management (NBIM)
0.31008%
Nippon Life India Asset Management Limited
Nippon Life India Asset Management Limited
0.25839%
BlackRock Advisors (UK) Limited
BlackRock Advisors (UK) Limited
...

Zydus Lifesciences Executives and Management Board

SP

Dr. Sharvil Patel

(45)

Managing Director, Executive Director · since 1997

Compensation300 M INR
GN

Mr. Ganesh Nayak

(69)

Executive Director · since 2017

Compensation140 M INR
NP

Mr. Nitin Parekh

Chief Financial Officer

Compensation54.31 M INR
SS

Shri. Bhadresh Shah

(72)

Non-Executive Independent Director

Compensation4.1 M INR
MP

Mr. Mukesh Patel

(70)

Non-Executive Director

Compensation4 M INR

Frequently asked questions about Zydus Lifesciences

The business model of Zydus Lifesciences Ltd is focused on pharmaceutical research, development, and manufacturing. As one of the leading pharmaceutical companies in India, Zydus Lifesciences Ltd aims to develop innovative and high-quality healthcare solutions to improve the well-being of people globally. They are committed to conducting extensive research, identifying unmet medical needs, and delivering cost-effective medications across various therapeutic areas. Zydus Lifesciences Ltd operates with a strong emphasis on ethical practices, compliance, and sustainable growth in the pharmaceutical industry. Their business model revolves around creating and delivering safe, reliable, and affordable pharmaceutical products to improve lives worldwide.

All fundamentals and in-depth analysis of Zydus Lifesciences

Our stock analysis for Zydus Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zydus Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Zydus Lifesciences Stock
Zydus Lifesciences Revenue→
Zydus Lifesciences Stock
Zydus Lifesciences Net Income→
Zydus Lifesciences Stock
Zydus Lifesciences P/E→
Zydus Lifesciences Stock
Zydus Lifesciences P/S→
Zydus Lifesciences Stock
Zydus Lifesciences EBIT→
Zydus Lifesciences Stock
Zydus Lifesciences Dividend→
Zydus Lifesciences Stock
Zydus Lifesciences Directors Dealings→
Zydus Lifesciences Stock
Zydus Lifesciences Stocks→
Zydus Lifesciences Stock
Zydus Lifesciences Market capitalization→
Zydus Lifesciences Stock
Zydus Lifesciences Debt→
Zydus Lifesciences Stock
Zydus Lifesciences Liabilities→
Zydus Lifesciences Stock
Zydus Lifesciences Equity→
Zydus Lifesciences Stock
Zydus Lifesciences AAQS→
Zydus Lifesciences Stock
Zydus Lifesciences Employees→
Zydus Lifesciences Stock
Zydus Lifesciences ROE→
Zydus Lifesciences Stock
Zydus Lifesciences ROA→
Zydus Lifesciences Stock
Zydus Lifesciences ROCE→